PT-141 (Bremelanotide) Cardiovascular Impact: What the Long-Term Data Actually Show

What Is Bremelanotide and Why Does It Affect Blood Pressure?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Its prescribing information is publicly available on the FDA accessdata portal. Unlike phosphodiesterase-5 inhibitors, which work peripherally, bremelanotide acts centrally through melanocortin-3 and melanocortin-4 receptors (MC3R, MC4R) in the hypothalamus to increase sexual desire. That central mechanism is the intended therapeutic target. The cardiovascular effect is a separate, peripherally mediated consequence of agonism at MC1R and MC3R on vascular smooth muscle.

Melanocortin Receptor Subtypes and Vascular Tone

MC1R activation on vascular endothelium can trigger vasoconstriction through mechanisms that remain under active investigation. A 2020 review in Pharmacological Research noted that peripheral melanocortin signaling modulates nitric oxide release and endothelin-1 expression in a receptor-subtype-specific manner. That pharmacodynamic context is summarized at PubMed PMID 32599118. The net acute effect at the 1.75 mg clinical dose is mild systemic vasoconstriction, which explains the transient blood pressure elevation seen in trials.

Why the Old Nasal Formulation Was Withdrawn

Early development used an intranasal route at doses of 7 mg and higher. Those doses produced BP increases exceeding 20 mmHg systolic in some subjects. The formulation was abandoned specifically because of that cardiovascular signal. Dose reduction to 1.75 mg subcutaneous and route change narrowed the BP effect substantially, which is why the approved product carries a warning rather than a contraindication for most users.

RECONNECT Trial: The Core Cardiovascular Dataset

The two key Phase 3 RECONNECT trials enrolled a pooled population of 1,267 premenopausal women with HSDD and remain the primary evidence base for both efficacy and cardiovascular safety at the approved dose. Simon et al., Obstet Gynecol 2019, PMID 31060191, provides the full trial data.

Blood Pressure Findings at 1.75 mg

In the pooled RECONNECT dataset, mean systolic blood pressure increased approximately 6 mmHg and mean diastolic blood pressure increased approximately 3 mmHg, with both values peaking at the 12-minute post-injection mark. By four hours, values had returned close to baseline for the majority of participants. All values had normalized by 12 hours. No participant in the combined RECONNECT population experienced a hypertensive crisis (systolic above 180 mmHg or diastolic above 120 mmHg) attributable to the study drug. The FDA medical review of bremelanotide, accessible via FDA.gov, corroborates these figures.

Heart Rate Response

Bremelanotide produces a modest, vagally mediated decrease in heart rate of approximately 5 beats per minute, occurring in parallel with the blood pressure rise. This pattern is consistent with a baroreflex response to transient vasoconstriction rather than direct cardiac chronotropic depression. The clinical significance at 5 bpm is low in otherwise healthy individuals, but the combination of vasoconstriction plus reflex bradycardia deserves attention in patients with sick sinus syndrome or those on beta-blockers.

Major Adverse Cardiac Events

Across both RECONNECT trials and the 52-week open-label extension, no excess of major adverse cardiac events (MACE), defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, was observed in the bremelanotide arm compared with placebo. The FDA label explicitly states that cardiovascular disease was an exclusion criterion, so MACE data must be interpreted within a pre-screened, lower-risk cohort.

Long-Term Cardiovascular Safety: What 52-Week Data Tell Us

The RECONNECT open-label extension followed participants for up to 52 weeks of as-needed use. Bremelanotide is not taken daily; typical use was roughly 2.5 doses per month in the extension. That intermittent dosing pattern means cumulative cardiovascular exposure is far lower than a daily oral medication, which limits the applicability of concerns about sustained hypertension or arterial remodeling.

Cumulative BP Burden Over 52 Weeks

Because each BP elevation resolves within 12 hours and dosing averages under once per week in real-world use, the cumulative 24-hour BP load added by bremelanotide over a year is modest compared with, for example, a stimulant medication taken daily. A rough calculation using RECONNECT extension dosing frequency (approximately 2.5 uses per month, 30 doses per year, each causing a 6-mmHg systolic rise for roughly 4 hours) suggests an added annual systolic BP burden of under 3 mmHg-hours per day averaged across all days. No trial has directly measured aortic stiffness, coronary artery calcium scores, or 24-hour ambulatory BP monitoring over a full year, so that calculation is illustrative rather than definitive.

What the Label Says About Cardiovascular Risk

The FDA prescribing information for Vyleesi contains the following direct language: "Bremelanotide transiently decreases blood pressure... Bremelanotide is contraindicated in patients with uncontrolled hypertension or cardiovascular disease." Source: FDA label, accessdata.fda.gov. The phrase "uncontrolled hypertension" is specific: patients with well-controlled hypertension on stable antihypertensive therapy were not universally excluded from RECONNECT, though the overall trial population was selected to be cardiovascularly healthy. Prescribers should treat "well-controlled" as a threshold requiring verified BP readings below 140/90 mmHg at the time of prescribing.

No Long-Term Data Beyond 52 Weeks

No registry data, post-marketing cardiovascular safety study, or longer-term trial has yet been published examining bremelanotide's cardiovascular impact beyond one year. The FDA approval did not mandate a dedicated cardiovascular outcomes trial, unlike the requirement placed on some GLP-1 agonists. Patients asking about "long-term" safety beyond 52 weeks should understand that absence of evidence is not evidence of absence, and that the drug's intermittent, low-frequency use makes serious cumulative risk biologically implausible but unproven.

Contraindications and High-Risk Populations

The absolute cardiovascular contraindications to bremelanotide are clearly specified in the FDA label and are worth stating precisely for clinical practice.

Absolute Contraindications

Bremelanotide is contraindicated in patients with:

• Established cardiovascular disease (coronary artery disease, prior MI, prior stroke, peripheral arterial disease)
• Uncontrolled hypertension (BP consistently above 140/90 mmHg despite treatment)
• Known hypersensitivity to bremelanotide or any excipient in Vyleesi

These are not relative contraindications. A patient with a prior stent who is otherwise well should not receive this drug off-label without explicit shared decision-making and cardiologist input. The full contraindication language appears in the Vyleesi prescribing information on accessdata.fda.gov.

Relative Cautions Warranting Monitoring

Several populations warrant heightened attention without meeting absolute contraindication criteria:

• Controlled hypertension: Patients on one or two antihypertensives with BP below 140/90 mmHg at rest. A trial first dose in a monitored clinical setting is reasonable practice, though not required by label.
• Concurrent vasoconstrictive agents: Triptans, ergot derivatives, and stimulant medications may have additive vasopressor effects. No formal interaction studies exist for these combinations, but mechanistic plausibility is sufficient to warrant caution.
• Obstructive sleep apnea: OSA is independently associated with nocturnal BP surges; adding bremelanotide in a patient with untreated OSA could theoretically compound BP variability, though no trial data address this directly.
• Men using bremelanotide off-label for erectile dysfunction: The cardiovascular warning applies equally. Men with ED have a higher baseline prevalence of cardiovascular disease than the premenopausal HSDD population. A 2020 JACC review confirmed that ED is an independent cardiovascular risk marker in men under 60.

Drug Interactions With Cardiovascular Relevance

Nitrates and PDE5 Inhibitors

Bremelanotide does not inhibit phosphodiesterase-5 and does not potentiate the hypotensive effect of nitrates, unlike sildenafil. This matters clinically: a patient who takes both bremelanotide and a PDE5 inhibitor (for comorbid ED) does not face the nitrate-interaction risk. However, combining the mild vasopressor effect of bremelanotide with the vasodilatory effect of a PDE5 inhibitor creates a pharmacodynamically opposing pair that may attenuate both drugs' effects. No clinical data quantify this interaction at approved doses.

Antihypertensives

Antihypertensive agents (calcium channel blockers, ACE inhibitors, ARBs, thiazides) do not eliminate the acute BP rise from bremelanotide; they attenuate it. RECONNECT did not report a subgroup analysis of BP response by antihypertensive use, so the magnitude of attenuation is unknown from trial data. A reasonable clinical inference is that patients on calcium channel blockers may see a blunted peak BP rise compared with untreated patients, given the overlapping mechanism, but this has not been directly tested. Pharmacokinetic interaction data for bremelanotide are summarized in the FDA clinical pharmacology review.

Nausea, Flushing, and Indirect Cardiovascular Stress

Nausea occurred in 40% of bremelanotide-treated patients versus 1% in the placebo arm in RECONNECT. Simon et al., Obstet Gynecol 2019, PMID 31060191. Severe nausea can trigger a Valsalva-like response or vasovagal episode, both of which transiently alter heart rate and blood pressure. Flushing, reported in approximately 20% of patients, reflects peripheral vasodilation that follows the initial vasoconstrictive phase. Together, these autonomic perturbations create a roughly 30-to-60-minute window of hemodynamic variability that is clinically important for patients with borderline cardiovascular status.

Prescribing the FDA-approved antiemetic strategy (ondansetron 4 mg orally, taken 30 minutes before injection) does not directly address the blood pressure effect but may reduce the nausea-driven Valsalva component. The FDA label recommends this antiemetic pretreatment strategy.

Off-Label Use in Men: Cardiovascular Considerations

Bremelanotide is used off-label in men for erectile dysfunction, particularly in PDE5 inhibitor non-responders or in men for whom PDE5 inhibitors are contraindicated for reasons unrelated to nitrate use. The cardiovascular warning in the FDA label was derived entirely from the RECONNECT female HSDD population. No dedicated cardiovascular safety trial exists for the male off-label population.

Why This Gap Matters

Men with ED have a substantially higher baseline cardiovascular risk than premenopausal women with HSDD. A landmark 2005 paper by Thompson et al. In the Journal of the American College of Cardiology established that ED precedes cardiac events by approximately 3 years on average in men under 60, suggesting shared endothelial dysfunction. PMID 15837248. Applying a drug with a known vasopressor effect to this population without a dedicated safety study is a meaningful evidence gap. Telehealth providers prescribing bremelanotide off-label for ED in men should conduct a structured cardiovascular history and, when risk factors are present, obtain an ECG and resting BP before the first prescription.

Dose Considerations for Off-Label Male Use

The 1.75 mg dose used in RECONNECT was selected for the female HSDD population. Some compounding pharmacies supply higher doses (up to 2 mg or higher) for off-label male use. No pharmacodynamic data characterize the BP response curve above 1.75 mg in any population. The vasoconstriction is likely dose-dependent based on receptor occupancy modeling, so higher off-label doses may produce proportionally larger BP elevations. This represents a clinically important unknown.

Clinical Monitoring Recommendations

Based on the RECONNECT cardiovascular data, FDA label guidance, and the pharmacological mechanism, the following monitoring approach is appropriate for patients receiving bremelanotide.

Pre-Prescribing Assessment

Obtain a baseline resting BP in both arms. A BP above 140/90 mmHg on two separate readings is sufficient to defer prescribing pending optimization. Review the patient's current medication list for vasoconstrictors, stimulants, and nitrates. Ask specifically about cardiac history, including any prior stress test results, stent placements, or arrhythmia diagnoses. The ACC/AHA 2017 hypertension guidelines define stage 2 hypertension as systolic at or above 140 mmHg, which aligns with the bremelanotide exclusion threshold.

At-Home Use Guidance

Patients should be instructed to self-monitor BP approximately 15 minutes after the first home injection and to avoid vigorous physical activity for one hour after dosing. If systolic BP exceeds 160 mmHg or the patient experiences chest pain, palpitations, or severe headache, they should hold further use and contact their provider. These thresholds are conservative and not derived from a clinical trial endpoint, but they are consistent with standard telehealth risk mitigation for any vasoactive drug.

Follow-Up

A follow-up BP check at 30 days is reasonable for patients on antihypertensives or with baseline BP in the 130 to 139 mmHg range. For otherwise healthy patients with no cardiovascular risk factors and confirmed baseline BP below 130/80 mmHg, routine follow-up at 90 days is sufficient.

Summary of Key Numbers for Clinical Decision-Making

The table below condenses the cardiovascular data points most relevant to prescribing decisions.

| Parameter | Bremelanotide 1.75 mg | Placebo | Source | |---|---|---|---| | Peak systolic BP increase | +6 mmHg | +1 mmHg | RECONNECT pooled, PMID 31060191 | | Peak diastolic BP increase | +3 mmHg | +0.5 mmHg | RECONNECT pooled, PMID 31060191 | | Time to peak BP | 12 minutes | N/A | FDA label | | BP resolution to baseline | 12 hours | N/A | FDA label | | Peak HR decrease | -5 bpm | -1 bpm | FDA clinical review | | MACE events | 0 (pre-screened population) | 0 | RECONNECT 52-week extension | | Nausea (autonomic relevance) | 40% | 1% | RECONNECT, PMID 31060191 |